Substance P and vasoactive intestinal peptide levels in middle ear effusions of children.

Eyigor H, Osma U, Yilmaz MD, Eyigor M, Gultekin M, Erin N

Acta oto-laryngologica12 Jun 2012Cited by 1 (Europe PMC)

PMID22691066DOI10.3109/00016489.2012.680981PepBankPUB-22691066

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In children with otitis media with effusion, mean VIP levels were 50.91 pg/ml in serous and 54.86 pg/ml in mucoid middle ear effusions.
In plain wordsIn children with middle ear fluid, the body's own VIP averaged 50.91 pg/ml in serous fluid and 54.86 pg/ml in mucoid fluid.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableMean VIP level in middle ear effusions by type
Study
n = 50
Outcome group
Endogenous peptide levels · Immune and inflammation
Measurements
Mean VIP
50.91 pg/ml
serous middle ear effusion
Mean VIP
54.86 pg/ml
mucoid middle ear effusion
Source sentences
Summary
the mean level of VIP was 50.91 ± 16.01 pg/ml in serous middle ear effusions and 54.86 ± 15.91 pg/ml in mucoid MEEs.
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty patients aged 2-12 years (mean age 5.24 ± 2.64) were included in the study.
Summary · context
SP and VIP levels were determined using ELISA.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2269106601
02HumanEndogenous levelObservational studyOther
In children with otitis media with effusion, VIP levels were undetectable in 30% of patients.
In plain wordsIn children with middle ear fluid, the body's own VIP could not be detected in 30% of patients.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableUndetectable VIP in middle ear effusions
Study
n = 50
Outcome group
Endogenous peptide levels · Immune and inflammation
Measurements
Patients with undetectable VIP
30%
otitis media with effusion
Source sentences
Summary
VIP levels were undetectable in 30% of patients
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty patients aged 2-12 years (mean age 5.24 ± 2.64) were included in the study.
Summary · context
SP and VIP levels were determined using ELISA.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2269106602
03HumanEndogenous levelObservational studyOther
In children with otitis media with effusion, VIP levels correlated inversely with substance P levels in middle ear effusions.
In plain wordsIn children with middle ear fluid, higher substance P was linked to lower levels of the body's own VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseCorrelation of VIP with substance P in effusions
Study
n = 50
Outcome group
Endogenous peptide levels · Immune and inflammation
Source sentences
Summary
This is the first report demonstrating high levels of substance P (SP) that inversely correlate with vasoactive intestinal peptide (VIP) levels in middle ear effusions (MEEs) of patients with otitis media with effusion (OME).
2 context sentences(design, population, supporting numbers)
Summary · context
Fifty patients aged 2-12 years (mean age 5.24 ± 2.64) were included in the study.
Summary · context
SP and VIP levels were determined using ELISA.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-2269106603

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:40 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.